Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey.
- 1 February 2003
- Vol. 32 (2) , 120-126
- https://doi.org/10.1016/s8756-3282(02)00946-8
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic WomenOsteoporosis International, 2002
- Fractures after Long-Term Alendronate TherapyJournal of Clinical Endocrinology & Metabolism, 2001
- Effect of Risedronate on the Risk of Hip Fracture in Elderly WomenNew England Journal of Medicine, 2001
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures studyThe American Journal of Medicine, 2000
- Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic WomenJournal of Clinical Endocrinology & Metabolism, 2000
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis: Efficacy and Safety After Seven Years of TreatmentThe American Journal of Medicine, 1997